BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, Ciafaloni E, Cunniff C, Druschel CM, Mathews KD, Matthews DJ, Meaney FJ, Andrews JG, Conway KM, Fox DJ, Street N, Adams MM, Bolen J; MD STARnet. Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics 2015;135:513-21. [PMID: 25687144 DOI: 10.1542/peds.2014-2044] [Cited by in Crossref: 109] [Cited by in F6Publishing: 95] [Article Influence: 15.6] [Reference Citation Analysis]
Number Citing Articles
1 Parvatiyar MS, Brownstein AJ, Kanashiro-Takeuchi RM, Collado JR, Dieseldorff Jones KM, Gopal J, Hammond KG, Marshall JL, Ferrel A, Beedle AM, Chamberlain JS, Renato Pinto J, Crosbie RH. Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy. JCI Insight 2019;5:123855. [PMID: 31039133 DOI: 10.1172/jci.insight.123855] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Duong T, Canbek J, Fernandez-Fernandez A, Henricson E, Birkmeier M, Siener C, Rocha CT, McDonald C, Gordish-Dressman H; CINRG Investigators. Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids. J Neuromuscul Dis 2021. [PMID: 34719507 DOI: 10.3233/JND-210724] [Reference Citation Analysis]
3 Mitelman O, Abdel-Hamid HZ, Byrne BJ, Connolly AM, Heydemann P, Proud C, Shieh PB, Wagner KR, Dugar A, Santra S, Signorovitch J, Goemans N, McDonald CM, Mercuri E, Mendell JR; investigators from the LNMRC Natural History study., investigators from the CINRG Duchenne National History Study., investigators from The DMD Italian Group. A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. J Neuromuscul Dis 2021. [PMID: 34420980 DOI: 10.3233/JND-210665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Xia Q, Huang X, Huang J, Zheng Y, March ME, Li J, Wei Y. The Role of Autophagy in Skeletal Muscle Diseases. Front Physiol 2021;12:638983. [PMID: 33841177 DOI: 10.3389/fphys.2021.638983] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Suslov V, Suslova G, Lytaev S. MRI Assessment of Motor Capabilities in Patients with Duchenne Muscular Dystrophy According to the Motor Function Measure Scale. Tomography 2022;8:948-60. [DOI: 10.3390/tomography8020076] [Reference Citation Analysis]
6 Gaffney L, Davis Z, Mora-Navarro C, Fisher MB, Freytes DO. Extracellular Matrix Hydrogels Promote Expression of Muscle-Tendon Junction Proteins. Tissue Eng Part A 2021. [PMID: 34375125 DOI: 10.1089/ten.TEA.2021.0070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang L, Xu M, Liu D, Liang Y, Feng P, Li H, Zhu Y, He R, Lin J, Zhang H, Liao Z, Zhang C. Serum creatinine as a biomarker for dystrophinopathy: a cross-sectional and longitudinal study. BMC Neurol 2021;21:372. [PMID: 34563158 DOI: 10.1186/s12883-021-02382-7] [Reference Citation Analysis]
8 Roth JD, Pariser JJ, Stout TE, Misseri R, Elliott SP. Presentation and Management Patterns of Lower Urinary Tract Symptoms in Adults Due to Rare Inherited Neuromuscular Diseases. Urology 2020;135:165-70. [PMID: 31626855 DOI: 10.1016/j.urology.2019.09.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Smith MG, Royer J, Mann JR, McDermott S. Using Administrative Data to Ascertain True Cases of Muscular Dystrophy: Rare Disease Surveillance. JMIR Public Health Surveill 2017;3:e2. [PMID: 28082256 DOI: 10.2196/publichealth.6720] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
10 Nuzzo JL. Men's health in the United States: a national health paradox. Aging Male 2020;23:42-52. [PMID: 31354093 DOI: 10.1080/13685538.2019.1645109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Stroh A, Desai J. Hand Gesture-based Artificial Neural Network Trained Hybrid Human–machine Interface System to Navigate a Powered Wheelchair. J Bionic Eng 2021;18:1045-58. [DOI: 10.1007/s42235-021-00074-z] [Reference Citation Analysis]
12 Tehrani KHN, Hajiloo M, Asadollahi E, Lagini FP. Prevalence of muscular dystrophy in patients with muscular disorders in Tehran, Iran. Eur J Transl Myol 2018;28:7380. [PMID: 29991987 DOI: 10.4081/ejtm.2018.7385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Nance ME, Hakim CH, Yang NN, Duan D. Nanotherapy for Duchenne muscular dystrophy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2018;10. [PMID: 28398005 DOI: 10.1002/wnan.1472] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
14 Kim S, Zhu Y, Romitti PA, Fox DJ, Sheehan DW, Valdez R, Matthews D, Barber BJ; MD STARnet. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy. Neuromuscul Disord 2017;27:730-7. [PMID: 28645460 DOI: 10.1016/j.nmd.2017.05.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
15 Frishman N, Conway KC, Andrews J, Oleson J, Mathews K, Ciafaloni E, Oleszek J, Lamb M, Matthews D, Paramsothy P, McKirgan L, Romitti P. Perceived quality of life among caregivers of children with a childhood-onset dystrophinopathy: a double ABCX model of caregiver stressors and perceived resources. Health Qual Life Outcomes 2017;15:33. [PMID: 28187773 DOI: 10.1186/s12955-017-0612-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
16 Nicolau S, Milone M, Liewluck T. Guidelines for genetic testing of muscle and neuromuscular junction disorders. Muscle Nerve 2021;64:255-69. [PMID: 34133031 DOI: 10.1002/mus.27337] [Reference Citation Analysis]
17 Marden JR, Santos C, Pfister B, Able R, Lane H, Somma M, Zhao J, Signorovitch J, Parsons J, Apkon S. Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes. J Comp Eff Res 2021. [PMID: 34275333 DOI: 10.2217/cer-2021-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Amoasii L, Long C, Li H, Mireault AA, Shelton JM, Sanchez-Ortiz E, McAnally JR, Bhattacharyya S, Schmidt F, Grimm D, Hauschka SD, Bassel-Duby R, Olson EN. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med 2017;9:eaan8081. [PMID: 29187645 DOI: 10.1126/scitranslmed.aan8081] [Cited by in Crossref: 108] [Cited by in F6Publishing: 91] [Article Influence: 27.0] [Reference Citation Analysis]
19 Zhang Y, Mann JR, James KA, McDermott S, Conway KM, Paramsothy P, Smith T, Cai B; MD STARnet. Duchenne and Becker Muscular Dystrophies' Prevalence in MD STARnet Surveillance Sites: An Examination of Racial and Ethnic Differences. Neuroepidemiology 2021;55:47-55. [PMID: 33477152 DOI: 10.1159/000512647] [Reference Citation Analysis]
20 Sztretye M, Szabó L, Dobrosi N, Fodor J, Szentesi P, Almássy J, Magyar ZÉ, Dienes B, Csernoch L. From Mice to Humans: An Overview of the Potentials and Limitations of Current Transgenic Mouse Models of Major Muscular Dystrophies and Congenital Myopathies. Int J Mol Sci 2020;21:E8935. [PMID: 33255644 DOI: 10.3390/ijms21238935] [Reference Citation Analysis]
21 Ghori FF, Wahid M. Induced pluripotent stem cells from urine of Duchenne muscular dystrophy patients. Pediatr Int 2021;63:1038-47. [PMID: 33599058 DOI: 10.1111/ped.14655] [Reference Citation Analysis]
22 Bucher F, Friedlander MS, Aguilar E, Kurihara T, Krohne TU, Usui Y, Friedlander M. The long dystrophin gene product Dp427 modulates retinal function and vascular morphology in response to age and retinal ischemia. Neurochemistry International 2019;129:104489. [DOI: 10.1016/j.neuint.2019.104489] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Tong YR, Geng C, Guan YZ, Zhao YH, Ren HT, Yao FX, Ling C, Wang DC, Chen L, Cui LY, Zhang SY, Dai Y. A Comprehensive Analysis of 2013 Dystrophinopathies in China: A Report From National Rare Disease Center. Front Neurol 2020;11:572006. [PMID: 33101180 DOI: 10.3389/fneur.2020.572006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 McPherson AC, McAdam L, Keenan S, Schwellnus H, Biddiss E, DeFinney A, English K. A feasibility study using solution-focused coaching for health promotion in children and young people with Duchenne muscular dystrophy. Dev Neurorehabil 2018;21:121-30. [PMID: 28272972 DOI: 10.1080/17518423.2017.1289271] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
25 Wei Y, Speechley KN, Zou G, Campbell C. Factors Associated With Health-Related Quality of Life in Children With Duchenne Muscular Dystrophy. J Child Neurol 2016;31:879-86. [PMID: 26863997 DOI: 10.1177/0883073815627879] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
26 Larkindale J, Abresch R, Aviles E, Bronson A, Chin J, Furlong P, Gordish-Dressman H, Habeeb-Louks E, Henricson E, Kroger H, Lynn C, Lynn S, Martin D, Nuckolls G, Rooney W, Romero K, Sweeney L, Vandenborne K, Walter G, Wolff J, Wong B, McDonald CM, Duchenne Regulatory Science Consortium Imaging-Dmd Consortium And The Cinrg Investigators MO. Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy. PLoS Curr 2017;9:ecurrents. [PMID: 28228973 DOI: 10.1371/currents.md.83071bbd728982f2f1073f4950e03586] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Naseem N, Jawad U. Enabling the disabled: Call for intercepting disability surge in Pakistan. J Family Med Prim Care 2017;6:721-3. [PMID: 29564251 DOI: 10.4103/jfmpc.jfmpc_50_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Kim J, Field A, Schultz KAP, Hill DA, Stewart DR. The prevalence of DICER1 pathogenic variation in population databases. Int J Cancer 2017;141:2030-6. [PMID: 28748527 DOI: 10.1002/ijc.30907] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
29 Kong R, Ma J, Beers B, Kaushik D, Lin E, Goodwin E, Colacino J, Bibbiani F. Metabolite V, an epoxide species is a minor circulating metabolite in humans following a single oral dose of deflazacort. Pharmacol Res Perspect 2020;8:e00677. [PMID: 33090712 DOI: 10.1002/prp2.677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Gissy JJ, Johnson T, Fox DJ, Kumar A, Ciafaloni E, van Essen AJ, Peay HL, Martin A, Lucas A, Finkel RS; MD STARnet. Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials. Neuromuscul Disord 2017;27:905-10. [PMID: 28739181 DOI: 10.1016/j.nmd.2017.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Gyimesi M, Horváth ÁI, Túrós D, Suthar SK, Pénzes M, Kurdi C, Canon L, Kikuti C, Ruppel KM, Trivedi DV, Spudich JA, Lőrincz I, Rauscher AÁ, Kovács M, Pál E, Komoly S, Houdusse A, Málnási-Csizmadia A. Single Residue Variation in Skeletal Muscle Myosin Enables Direct and Selective Drug Targeting for Spasticity and Muscle Stiffness. Cell 2020;183:335-346.e13. [PMID: 33035452 DOI: 10.1016/j.cell.2020.08.050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Counterman KJ, Furlong P, Wang RT, Martin AS. Delays in diagnosis of Duchenne muscular dystrophy: An evaluation of genotypic and sociodemographic factors. Muscle Nerve 2020;61:36-43. [PMID: 31573675 DOI: 10.1002/mus.26720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sahay KM, Smith T, Conway KM, Romitti PA, Lamb MM, Andrews J, Pandya S, Oleszek J, Cunniff C, Valdez R. A Review of MD STAR net's Research Contributions to Pediatric-Onset Dystrophinopathy in the United States; 2002-2017. J Child Neurol 2019;34:44-53. [PMID: 30345857 DOI: 10.1177/0883073818801704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Law ML, Cohen H, Martin AA, Angulski ABB, Metzger JM. Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies. J Clin Med 2020;9:E520. [PMID: 32075145 DOI: 10.3390/jcm9020520] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
35 Gotthelf M, Townsend D, Durfee W. A video game based hand grip system for measuring muscle force in children. J Neuroeng Rehabil 2021;18:113. [PMID: 34246310 DOI: 10.1186/s12984-021-00908-1] [Reference Citation Analysis]
36 Wang RT, Nelson SF. What can Duchenne Connect teach us about treating Duchenne muscular dystrophy? Curr Opin Neurol 2015;28:535-41. [PMID: 26356412 DOI: 10.1097/WCO.0000000000000245] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Hadwen J, Farooq F, Witherspoon L, Schock S, Mongeon K, MacKenzie A. Anisomycin Activates Utrophin Upregulation Through a p38 Signaling Pathway. Clin Transl Sci 2018;11:506-12. [PMID: 29877606 DOI: 10.1111/cts.12562] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
38 Latimer R, Street N, Conway KC, James K, Cunniff C, Oleszek J, Fox D, Ciafaloni E, Westfield C, Paramsothy P; Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STAR net). Secondary Conditions Among Males With Duchenne or Becker Muscular Dystrophy. J Child Neurol 2017;32:663-70. [PMID: 28393671 DOI: 10.1177/0883073817701368] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
39 Wittlieb-Weber CA, Villa CR, Conway J, Bock MJ, Gambetta KE, Johnson JN, Lal AK, Schumacher KR, Law SP, Deshpande SR, West SC, Friedland-Little JM, Lytrivi ID, McCulloch MA, Butts RJ, Weber DR, Knecht KR. Use of advanced heart failure therapies in Duchenne muscular dystrophy. Prog Pediatr Cardiol 2019;53:11-4. [PMID: 31360053 DOI: 10.1016/j.ppedcard.2019.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
40 Xia G, Terada N, Ashizawa T. Human iPSC Models to Study Orphan Diseases: Muscular Dystrophies. Curr Stem Cell Rep 2018;4:299-309. [PMID: 30524939 DOI: 10.1007/s40778-018-0145-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
41 McDonald CM, Mercuri E. Evidence-based care in Duchenne muscular dystrophy. Lancet Neurol 2018;17:389-91. [PMID: 29656735 DOI: 10.1016/S1474-4422(18)30115-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
42 Vather-Wu N, Krasowski MD, Mathews KD, Shibli-Rahhal A. Vitamin D Level Stability in Dystrophinopathy Patients on Vitamin D Supplementation. J Neuromuscul Dis 2021;8:481-7. [PMID: 33814459 DOI: 10.3233/JND-200625] [Reference Citation Analysis]
43 Yan D, Li Q, Lin CW, Shieh JY, Weng WC, Tsui PH. Clinical Evaluation of Duchenne Muscular Dystrophy Severity Using Ultrasound Small-Window Entropy Imaging. Entropy (Basel) 2020;22:E715. [PMID: 33286487 DOI: 10.3390/e22070715] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
44 Tucker-Bartley A, Lemme J, Gomez-Morad A, Shah N, Veliu M, Birklein F, Storz C, Rutkove S, Kronn D, Boyce AM, Kraft E, Upadhyay J. Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases. Neurosci Biobehav Rev 2021;124:267-90. [PMID: 33581222 DOI: 10.1016/j.neubiorev.2021.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Mathews KD, Conway KM, Gedlinske AM, Johnson N, Street N, Butterfield RJ, Hung M, Ciafaloni E, Romitti PA. Characteristics of Clinical Trial Participants with Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Children (Basel) 2021;8:835. [PMID: 34682100 DOI: 10.3390/children8100835] [Reference Citation Analysis]
46 Shing JZ, Liu T, Valdez R. Changes in care coordination and health insurance in the population of US children with muscular dystrophy, 2005-2006 and 2009-2010. Int J Care Coord 2018;21:140-52. [PMID: 30873286 DOI: 10.1177/2053434518818448] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Ciafaloni E, Kumar A, Liu K, Pandya S, Westfield C, Fox DJ, Caspers Conway KM, Cunniff C, Mathews K, West N, Romitti PA, McDermott MP. Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet. J Pediatr Rehabil Med 2016;9:5-11. [PMID: 26966795 DOI: 10.3233/PRM-160361] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
48 Soelaeman RH, Smith MG, Sahay K, Tilford JM, Goodenough D, Paramsothy P, Ouyang L, Oleszek J, Grosse SD. Labor market participation and productivity costs for female caregivers of minor male children with Duchenne and Becker muscular dystrophies. Muscle Nerve 2021;64:717-25. [PMID: 34605048 DOI: 10.1002/mus.27429] [Reference Citation Analysis]
49 Hiraide T, Ogata T, Watanabe S, Nakashima M, Fukuda T, Saitsu H. Coexistence of a CAV3 mutation and a DMD deletion in a family with complex muscular diseases. Brain and Development 2019;41:474-9. [DOI: 10.1016/j.braindev.2019.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Niranjan N, Mareedu S, Tian Y, Kodippili K, Fefelova N, Voit A, Xie LH, Duan D, Babu GJ. Sarcolipin overexpression impairs myogenic differentiation in Duchenne muscular dystrophy. Am J Physiol Cell Physiol 2019;317:C813-24. [PMID: 31365291 DOI: 10.1152/ajpcell.00146.2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
51 Dubinin MV, Starinets VS, Talanov EY, Mikheeva IB, Belosludtseva NV, Serov DA, Tenkov KS, Belosludtseva EV, Belosludtsev KN. Effect of the Non-Immunosuppressive MPT Pore Inhibitor Alisporivir on the Functioning of Heart Mitochondria in Dystrophin-Deficient mdx Mice. Biomedicines 2021;9:1232. [PMID: 34572419 DOI: 10.3390/biomedicines9091232] [Reference Citation Analysis]
52 Sanchez F, Weitz C, Gutierrez JM, Mestroni L, Hanneman K, Vargas D. Cardiac MR Imaging of Muscular Dystrophies. Curr Probl Diagn Radiol 2021:S0363-0188(21)00023-2. [PMID: 33551194 DOI: 10.1067/j.cpradiol.2020.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Vermeulen KM, Lopes MMGD, Grilo EC, Alves CX, Machado RJA, Lais LL, Brandão-Neto J, Vale SHL. Bioelectrical impedance vector analysis and phase angle in boys with Duchenne muscular dystrophy. Food Nutr Res 2019;63. [PMID: 31007651 DOI: 10.29219/fnr.v63.1615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
54 Mejia EJ, Lin KY, Okunowo O, Iacobellis KA, Matesanz SE, Brandsema JF, Wittlieb-Weber CA, Katcoff H, Griffis H, Edelson JB. Health Care Use of Cardiac Specialty Care in Children With Muscular Dystrophy in the United States. J Am Heart Assoc 2022;:e024722. [PMID: 35411787 DOI: 10.1161/JAHA.121.024722] [Reference Citation Analysis]
55 Vergara HM, Ramirez J, Rosing T, Nave C, Blandino R, Saw D, Saraf P, Piexoto G, Coombes C, Adams M, Domingo CR. miR-206 is required for changes in cell adhesion that drive muscle cell morphogenesis in Xenopus laevis. Dev Biol 2018;438:94-110. [PMID: 29596841 DOI: 10.1016/j.ydbio.2018.03.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
56 Lee S, Lee M, Hor KN. The role of imaging in characterizing the cardiac natural history of Duchenne muscular dystrophy. Pediatr Pulmonol 2021;56:766-81. [PMID: 33651923 DOI: 10.1002/ppul.25227] [Reference Citation Analysis]
57 Ma J, Beers B, Manohar R, Roe S, Colacino JM, Kong R. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort. Pharmacol Res Perspect 2021;9:e00748. [PMID: 33749127 DOI: 10.1002/prp2.748] [Reference Citation Analysis]
58 Kwiatkowski TA, Rose AL, Jung R, Capati A, Hallak D, Yan R, Weisleder N. Multiple poloxamers increase plasma membrane repair capacity in muscle and nonmuscle cells. Am J Physiol Cell Physiol 2020;318:C253-62. [PMID: 31747313 DOI: 10.1152/ajpcell.00321.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
59 Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res 2016;44:6549-63. [PMID: 27288447 DOI: 10.1093/nar/gkw533] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 34.0] [Reference Citation Analysis]
60 Dowling JJ, D Gonorazky H, Cohn RD, Campbell C. Treating pediatric neuromuscular disorders: The future is now. Am J Med Genet A 2018;176:804-41. [PMID: 28889642 DOI: 10.1002/ajmg.a.38418] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
61 Marozzo R, Pegoraro V, Angelini C. MiRNAs, Myostatin, and Muscle MRI Imaging as Biomarkers of Clinical Features in Becker Muscular Dystrophy. Diagnostics (Basel) 2020;10:E713. [PMID: 32961888 DOI: 10.3390/diagnostics10090713] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
62 Maleiner B, Tomasch J, Heher P, Spadiut O, Rünzler D, Fuchs C. The Importance of Biophysical and Biochemical Stimuli in Dynamic Skeletal Muscle Models. Front Physiol 2018;9:1130. [PMID: 30246791 DOI: 10.3389/fphys.2018.01130] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
63 Vianello A, Arcaro G, Guarnieri G, Sukthi A, Molena B, Turato C, Braccioni F, Gallan F, Lugato F, Turrin M, Bello L, Navalesi P. Non-Invasive Ventilation for Acute Respiratory Failure in Duchenne Muscular Dystrophy Patients. Arch Bronconeumol (Engl Ed) 2021:S0300-2896(21)00037-5. [PMID: 33676781 DOI: 10.1016/j.arbres.2021.01.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Conway KM, Gedlinske A, Mathews KD, Perlman S, Johnson N, Butterfield R, Hung M, Bounsanga J, Matthews D, Oleszek J, Romitti PA. A population-based study of scoliosis among males diagnosed with a dystrophinopathy identified by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Muscle Nerve 2021. [PMID: 34787322 DOI: 10.1002/mus.27464] [Reference Citation Analysis]
65 Filareto A, Maguire-Nguyen K, Gan Q, Aldanondo G, Machado L, Chamberlain JS, Rando TA. Monitoring disease activity noninvasively in the mdx model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2018;115:7741-6. [PMID: 29987034 DOI: 10.1073/pnas.1802425115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
66 Weber DR, Thomas S, Erickson SW, Fox D, Oleszek J, Pandya S, Venkatesh Y, Westfield C, Ciafaloni E; Muscular Dystrophy Tracking and Research Network (MD STAR. Bone Health and Endocrine Care of Boys with Duchenne Muscular Dystrophy: Data from the MD STARnet. J Neuromuscul Dis 2018;5:497-507. [PMID: 30149461 DOI: 10.3233/JND-180317] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
67 Aeffner F, Faelan C, Moore SA, Moody A, Black JC, Charleston JS, Frank DE, Dworzak J, Piper JK, Ranjitkar M, Wilson K, Kanaly S, Rudmann DG, Lange H, Young GD, Milici AJ. Validation of a Muscle-Specific Tissue Image Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies. Arch Pathol Lab Med 2019;143:197-205. [PMID: 30168727 DOI: 10.5858/arpa.2017-0536-OA] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Conrado DJ, Larkindale J, Berg A, Hill M, Burton J, Abrams KR, Abresch RT, Bronson A, Chapman D, Crowther M, Duong T, Gordish-dressman H, Harnisch L, Henricson E, Kim S, Mcdonald CM, Schmidt S, Vong C, Wang X, Wong BL, Yong F, Romero K; the Duchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC). Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy. J Pharmacokinet Pharmacodyn 2019;46:441-55. [DOI: 10.1007/s10928-019-09642-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
69 Gawlik KI. At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients? Int J Mol Sci 2018;19:E1490. [PMID: 29772730 DOI: 10.3390/ijms19051490] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
70 Timpani CA, Hayes A, Rybalka E. Revisiting the dystrophin-ATP connection: How half a century of research still implicates mitochondrial dysfunction in Duchenne Muscular Dystrophy aetiology. Med Hypotheses 2015;85:1021-33. [PMID: 26365249 DOI: 10.1016/j.mehy.2015.08.015] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 9.3] [Reference Citation Analysis]
71 Lopez C, Batra A, Moslemi Z, Rennick A, Guice K, Zeng H, Walter GA, Forbes SC. Effects of muscle damage on 31 phosphorus magnetic resonance spectroscopy indices of energetic status and sarcolemma integrity in young mdx mice. NMR Biomed 2021;:e4659. [PMID: 34841594 DOI: 10.1002/nbm.4659] [Reference Citation Analysis]
72 Turk MA, McDermott S. Support for research about disability and health. Disabil Health J 2016;9:557-8. [PMID: 27637293 DOI: 10.1016/j.dhjo.2016.07.003] [Reference Citation Analysis]
73 Nguyen TNT, Sha S, Hong MS, Maloney AJ, Barone PW, Neufeld C, Wolfrum J, Springs SL, Sinskey AJ, Braatz RD. Mechanistic model for production of recombinant adeno-associated virus via triple transfection of HEK293 cells. Mol Ther Methods Clin Dev 2021;21:642-55. [PMID: 34095346 DOI: 10.1016/j.omtm.2021.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Crist C. Emerging new tools to study and treat muscle pathologies: genetics and molecular mechanisms underlying skeletal muscle development, regeneration, and disease. J Pathol 2017;241:264-72. [PMID: 27762447 DOI: 10.1002/path.4830] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
75 Carlson CR, Moore SA, Mathews KD. Dystrophinopathy muscle biopsies in the genetic testing ERA: One center's data. Muscle Nerve 2018. [PMID: 29365344 DOI: 10.1002/mus.26083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Orsso CE, Tibaes JRB, Oliveira CLP, Rubin DA, Field CJ, Heymsfield SB, Prado CM, Haqq AM. Low muscle mass and strength in pediatrics patients: Why should we care? Clin Nutr 2019;38:2002-15. [PMID: 31031136 DOI: 10.1016/j.clnu.2019.04.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
77 Bendixen RM, Morgenroth LP, Clinard KL. Engaging Participants in Rare Disease Research: A Qualitative Study of Duchenne Muscular Dystrophy. Clinical Therapeutics 2016;38:1474-1484.e2. [DOI: 10.1016/j.clinthera.2016.04.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
78 Holland A, Murphy S, Dowling P, Ohlendieck K. Pathoproteomic profiling of the skeletal muscle matrisome in dystrophinopathy associated myofibrosis. Proteomics 2016;16:345-66. [PMID: 26256116 DOI: 10.1002/pmic.201500158] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
79 Andrews JG, Wahl RA. Duchenne and Becker muscular dystrophy in adolescents: current perspectives. Adolesc Health Med Ther 2018;9:53-63. [PMID: 29588625 DOI: 10.2147/AHMT.S125739] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
80 Do TN, Street N, Donnelly J, Adams MM, Cunniff C, Fox DJ, Weinert RO, Oleszek J, Romitti PA, Westfield CP, Bolen J; Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Muscular Dystrophy Surveillance, Tracking, and Research Network pilot: Population-based surveillance of major muscular dystrophies at four U.S. sites, 2007-2011. Birth Defects Res 2018;110:1404-11. [PMID: 30070776 DOI: 10.1002/bdr2.1371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
81 Rodgers BD, Bishaw Y, Kagel D, Ramos JN, Maricelli JW. Micro-dystrophin Gene Therapy Partially Enhances Exercise Capacity in Older Adult mdx Mice. Mol Ther Methods Clin Dev 2020;17:122-32. [PMID: 31909085 DOI: 10.1016/j.omtm.2019.11.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
82 Hayes EA, Nandi D. Is there a future for the use of left ventricular assist devices in Duchenne muscular dystrophy? Pediatr Pulmonol 2021;56:753-9. [PMID: 33245216 DOI: 10.1002/ppul.25181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Matsuo M. Investigational treatments and therapeutic targets in Becker muscular dystrophy. Expert Opinion on Orphan Drugs 2015;3:821-9. [DOI: 10.1517/21678707.2015.1057117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
84 Bendixen RM, Houtrow A. Parental Reflections on the Diagnostic Process for Duchenne Muscular Dystrophy: A Qualitative Study. J Pediatr Health Care 2017;31:285-92. [PMID: 27743907 DOI: 10.1016/j.pedhc.2016.09.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
85 Hagan M, Ashraf M, Kim IM, Weintraub NL, Tang Y. Effective regeneration of dystrophic muscle using autologous iPSC-derived progenitors with CRISPR-Cas9 mediated precise correction. Med Hypotheses 2018;110:97-100. [PMID: 29317080 DOI: 10.1016/j.mehy.2017.11.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
86 Okazaki T, Matsuura K, Kasagi N, Adachi K, Kai M, Okubo M, Nishino I, Nanba E, Maegaki Y. Duchenne muscular dystrophy-like phenotype in an LGMD2I patient with novel FKRP gene variants. Hum Genome Var 2020;7:12. [PMID: 32351701 DOI: 10.1038/s41439-020-0099-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M, Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12:79. [PMID: 28446219 DOI: 10.1186/s13023-017-0631-3] [Cited by in Crossref: 143] [Cited by in F6Publishing: 137] [Article Influence: 28.6] [Reference Citation Analysis]
88 Barnard AM, Riehl SL, Willcocks RJ, Walter GA, Angell AM, Vandenborne K. Characterizing Enrollment in Observational Studies of Duchenne Muscular Dystrophy by Race and Ethnicity. J Neuromuscul Dis 2020;7:167-73. [PMID: 31929119 DOI: 10.3233/JND-190447] [Reference Citation Analysis]
89 Paramsothy P, Wang Y, Cai B, Conway KM, Johnson NE, Pandya S, Ciafaloni E, Mathews KD, Romitti PA, Howard JF, Riley C. Selected clinical and demographic factors and all-cause mortality among individuals with Duchenne muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking, and Research Network. Neuromuscular Disorders 2022. [DOI: 10.1016/j.nmd.2022.04.008] [Reference Citation Analysis]
90 Schultz TI, Raucci FJ, Salloum FN. Cardiovascular Disease in Duchenne Muscular Dystrophy. JACC: Basic to Translational Science 2022;7:608-25. [DOI: 10.1016/j.jacbts.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Reichard A, McDermott S, Ruttenber M, Mann J, Smith MG, Royer J, Valdez R. Testing the Feasibility of a Passive and Active Case Ascertainment System for Multiple Rare Conditions Simultaneously: The Experience in Three US States. JMIR Public Health Surveill 2016;2:e151. [PMID: 27574026 DOI: 10.2196/publichealth.5516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
92 Duong T, Canbek J, Birkmeier M, Nelson L, Siener C, Fernandez-Fernandez A, Henricson E, McDonald CM, Gordish-Dressman H; CINRG-DNHS Investigators. The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD. J Neuromuscul Dis 2021. [PMID: 34151852 DOI: 10.3233/JND-210646] [Reference Citation Analysis]
93 Salari N, Fatahi B, Valipour E, Kazeminia M, Fatahian R, Kiaei A, Shohaimi S, Mohammadi M. Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis. J Orthop Surg Res 2022;17:96. [PMID: 35168641 DOI: 10.1186/s13018-022-02996-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Wilson K, Faelan C, Patterson-Kane JC, Rudmann DG, Moore SA, Frank D, Charleston J, Tinsley J, Young GD, Milici AJ. Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification. Toxicol Pathol 2017;45:961-76. [PMID: 28974147 DOI: 10.1177/0192623317734823] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
95 Bowden SA, Connolly AM, Kinnett K, Zeitler PS. Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations. J Neuromuscul Dis 2019;6:31-41. [PMID: 30614808 DOI: 10.3233/JND-180346] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
96 Raccah BH, Biton B, Amir O, Gotsman I, Nahman D, Matok I. Anti-Remodeling Cardiac Therapy in Patients With Duchenne Muscular Dystrophy, Meta-Analysis Study. Front Pharmacol 2022;12:769896. [DOI: 10.3389/fphar.2021.769896] [Reference Citation Analysis]
97 Awa HDM, Mvondo RMN, Nguefack S, Messanga CB, Ndombo POK. [Rare diseases and their clinical oral manifestations in two Hospitals in Yaoundé]. Pan Afr Med J 2019;32:195. [PMID: 31312307 DOI: 10.11604/pamj.2019.32.195.14684] [Reference Citation Analysis]
98 Nizamis K, Rijken NHM, Mendes A, Janssen MMHP, Bergsma A, Koopman BFJM. A Novel Setup and Protocol to Measure the Range of Motion of the Wrist and the Hand. Sensors (Basel) 2018;18:E3230. [PMID: 30257521 DOI: 10.3390/s18103230] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
99 James KA, Gralla J, Ridall LA, Do TN, Czaja AS, Mourani PM, Ciafaloni E, Cunniff C, Donnelly J, Oleszek J, Pandya S, Price E, Yang ML, Auerbach SR. Left ventricular dysfunction in Duchenne muscular dystrophy. Cardiol Young 2020;30:171-6. [PMID: 31964455 DOI: 10.1017/S1047951119002610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Lau YS, Zhao L, Zhang C, Li H, Han R. Genetic disruption of the inflammasome adaptor ASC has minimal impact on the pathogenesis of Duchenne muscular dystrophy in mdx mice. Life Sci 2020;257:118069. [PMID: 32659370 DOI: 10.1016/j.lfs.2020.118069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Kichula EA. Inherited Neuromuscular Disorders: Presentation, Diagnosis, and Advances in Treatment. Curr Pediatr Rep 2017;5:36-44. [DOI: 10.1007/s40124-017-0118-7] [Reference Citation Analysis]
102 Alfano LN, Miller NF, Berry KM, Yin H, Rolf KE, Flanigan KM, Mendell JR, Lowes LP. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscular Disorders 2017;27:452-7. [DOI: 10.1016/j.nmd.2017.02.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
103 Wittlieb-Weber CA, Knecht KR, Villa CR, Cunningham C, Conway J, Bock MJ, Gambetta KE, Lal AK, Schumacher KR, Law SP, Deshpande SR, West SC, Friedland-Little JM, Lytrivi ID, McCulloch MA, Butts RJ, Weber DR, Johnson JN. Risk Factors for Cardiac and Non-cardiac Causes of Death in Males with Duchenne Muscular Dystrophy. Pediatr Cardiol 2020;41:764-71. [PMID: 32016582 DOI: 10.1007/s00246-020-02309-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
104 Zimowski JG, Pilch J, Pawelec M, Purzycka JK, Kubalska J, Ziora-Jakutowicz K, Dudzińska M, Zaremba J. A rare subclinical or mild type of Becker muscular dystrophy caused by a single exon 48 deletion of the dystrophin gene. J Appl Genet 2017;58:343-7. [PMID: 28247318 DOI: 10.1007/s13353-017-0391-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
105 Sattenapalli NC, Areti AR, G. SKR, Kulandaivelu US, Alavala RR, Manne R. Study of Clinical Features and Diagnosis Pattern of Duchene Muscular Dystrophy in Southern India. J Neurosci Rural Pract. [DOI: 10.1055/s-0041-1740614] [Reference Citation Analysis]
106 Iftikhar M, Frey J, Shohan MJ, Malek S, Mousa SA. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy. Pharmacol Ther 2021;220:107719. [PMID: 33130193 DOI: 10.1016/j.pharmthera.2020.107719] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
107 Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis 2020;15:141. [PMID: 32503598 DOI: 10.1186/s13023-020-01430-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
108 Smith LR, Barton ER. Regulation of fibrosis in muscular dystrophy. Matrix Biol 2018;68-69:602-15. [PMID: 29408413 DOI: 10.1016/j.matbio.2018.01.014] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 11.3] [Reference Citation Analysis]
109 Hong Y, Wang Y, Zhang Y, Royer JA, Cai B, Mann JR, Mcdermott S. Risk factors for falls among boys under 18 years with muscular dystrophy. PRM 2019;12:3-10. [DOI: 10.3233/prm-170511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
110 Dubinin MV, Talanov EY, Tenkov KS, Starinets VS, Belosludtseva NV, Belosludtsev KN. The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy. Int J Mol Sci 2020;21:E8763. [PMID: 33228255 DOI: 10.3390/ijms21228763] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
111 Conway KM, Ciafaloni E, Matthews D, Westfield C, James K, Paramsothy P, Romitti PA. Application of the International Classification of Functioning, Disability and Health system to symptoms of the Duchenne and Becker muscular dystrophies. Disabil Rehabil 2018;40:1773-80. [PMID: 28395534 DOI: 10.1080/09638288.2017.1312567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
112 Al-Zougbi A, Mathews KD, Shibli-Rahhal A. Use of bone age for evaluating bone density in patients with Duchenne muscular dystrophy: A preliminary report. Muscle Nerve 2019;59:422-5. [PMID: 30636004 DOI: 10.1002/mus.26413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
113 Sarrazin E, Valard-Giguet AG, Leturcq F, Bellance R. [An overview of Duchenne muscular dystrophy in Martinique]. Med Sci (Paris) 2018;34 Hors série n°2:45-8. [PMID: 30418149 DOI: 10.1051/medsci/201834s215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Al-Khalili Szigyarto C. Duchenne Muscular Dystrophy: recent advances in protein biomarkers and the clinical application. Expert Rev Proteomics 2020;17:365-75. [PMID: 32713262 DOI: 10.1080/14789450.2020.1773806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
115 Pandya S, Andrews J, Campbell K, Meaney FJ. Rehabilitative technology use among individuals with Duchenne/Becker muscular dystrophy. J Pediatr Rehabil Med 2016;9:45-53. [PMID: 26966800 DOI: 10.3233/PRM-160356] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
116 Obeidat HM, Al Hadid LA, Al-Sagarat AY, Khrisat M. Lived Experience of Jordanian Parents Having a Child with Duchenne Muscular Dystrophy. J Pediatr Nurs 2021;57:5-10. [PMID: 33207304 DOI: 10.1016/j.pedn.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]